

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

(sied. 13.06.05)

To:

see form PCT/ISA/220

PCT

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)

Date of mailing
(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference
see form PCT/ISA/220

FOR FURTHER ACTION

See paragraph 2 below

International application No. PCT/EP2004/006330	International filing date (day/month/year) 11.06.2004	Priority date (day/month/year) 13.06.2003
--	--	--

International Patent Classification (IPC) or both national classification and IPC
C07C235/52, C07D333/08, C07D209/04, C07D241/40, C07D213/02, A61K31/166, A61K31/381, A61K31/404,

Applicant
LABORATORIOS S.A.L.V.A.T., S.A.

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer

Goetz, G

Telephone No. +49 89 2399-8105



BEST AVAILABLE COPY

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/EP2004/006330

Box No. I Basis of the opinion

1. With regard to the **language**, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material:
 - a sequence listing
 - table(s) related to the sequence listing
 - b. format of material:
 - in written format
 - in computer readable form
 - c. time of filing/furnishing:
 - contained in the international application as filed.
 - filed together with the international application in computer readable form.
 - furnished subsequently to this Authority for the purposes of search.
3. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

BEST AVAILABLE COPY

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/EP2004/006330

Box No. II Priority

1. The following document has not been furnished:

- copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).
- translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).

Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on the assumption that the relevant date is the claimed priority date.

2. This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.

3. It has not been possible to consider the validity of the priority claim because a copy of the priority document was not available to the ISA at the time that the search was conducted (Rule 17.1). This opinion has nevertheless been established on the assumption that the relevant date is the claimed priority date.

4. Additional observations, if necessary:

BEST AVAILABLE COPY

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/EP2004/006330

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

the entire international application,
 claims Nos. 30 - 38

because:

the said international application, or the said claims Nos. 30 - 38 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
 the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
 no international search report has been established for the whole application or for said claims Nos.
 the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form

has not been furnished
 does not comply with the standard

the computer readable form

has not been furnished
 does not comply with the standard

the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.

See separate sheet for further details

BEST AVAILABLE COPY

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/EP2004/006330

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or
industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims	1-38
	No:	Claims	
Inventive step (IS)	Yes:	Claims	13
	No:	Claims	1-12,14-38
Industrial applicability (IA)	Yes:	Claims	1-30
	No:	Claims	

2. Citations and explanations

see separate sheet

BEST AVAILABLE COPY

D1: WO 00/55118 A (GLAXO GROUP LTD ; BLANCHARD STEVEN GERARD (US); COBB JEFFERY EDMUND (U) 21 September 2000 (2000-09-21)
D2: WO 97/27847 A (PATCHETT ARTHUR A ; BERGER JOEL P (US); MERCK & CO INC (US); MOLLER DA 7 August 1997 (1997-08-07)

1. For the assessment of the present claims 30 to 38 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Claims 30 - 38 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

2. The claimed compounds differ from the compounds disclosed in D1 by the fact that in D1 the phenyl-ring of the benzamid-group is substituted by a nitro group and a group "X" whereas the claimed compounds do not have such a substitution pattern.
The claimed compounds differ from the compounds disclosed in D2 by the fact that D2 does not disclose benzamid-derivatives.
The subject matter of present claims 1 to 38 is thus considered to be novel over said prior art (PCT Article 33.2).
3. In view of D1 which is considered to represent the closest prior art the underlying problem can be defined by the provision of further compounds acting as modulators of PPAR-gamma.

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/EP2004/006330

To represent a solution it has to be shown that all compounds falling within the scope of formula (I) of claim 1 show this activity. In particular a representative number of benzamides falling within the structure of formula (I) but having different substitution pattern have to be tested and proven for their activity. Only if examples are given which cover the different structural possibilities as mentioned in claim 1 the underlying problem can be considered as being solved over the whole scope of the general formula (I) of claim 1. In the present case only a limited number of compounds has been tested compared with the broad scope of the general formula (I). These compounds (as mentioned in claim 13) are considered as solving the underlying problem. However, these compounds of claim 13 cannot be considered as being obvious alternatives to all the compounds falling within the scope of the general formula (I) of claim 1. Consequently present claims 1 to 12 and 14 to 38 are not considered to solve the underlying problem and are therefore considered not to be based on an inventive step (PCT Article 33.3).

BEST AVAILABLE COPY